CG Oncology, Inc. announced that it expects to receive $59.999999 million in funding
March 25, 2020
Share
CG Oncology, Inc. announced that it will issue 67,575,176 series D preferred shares at issue price of $0.8879 per share for the gross proceeds $59,999,998.7704 in funding on March 26, 2020. The shares are convertible, participating, redeemable and cumulative. The shares carry cumulative dividend rate of 8% per annum. The shares will be convertible in common shares at a price of $0.8879 per share.
On same date, the company issued 33,787,589 shares and received $30,000,000 in its first tranche. The transaction included participation from new investor Kissei Pharmaceutical Co., Ltd. (TSE:4547).
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
KISSEI PHARMACEUTICAL CO., LTD. 
